Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I guess there is nothing wrong with the full documentation, nor is there a tone of spite. I prefer not to have dirty laundry at all, but that's business. If it is there, I'm glad it is exposed. Hiding it is dirtier.
The 8k does reveal two concerns for me. First, why the inherent disrespect towards the Chief Executive? Second, and perhaps this relates to the first, is Mullan dedicating the amount of time and interaction necessary to effectively fulfill his responsibility as Rock Creek's leader?
What is the story with that? This is all I could find:
From the Annual Report PR:
Annual Meeting
The Company's annual meeting will be held on April 10, 2015 in Sarasota, Florida and will be accessible through a live webcast. In addition to the conduct of corporate matters at that meeting, the Company will hold a shareholder vote to conduct a reverse split at an appropriate ratio to insure compliance with Nasdaq minimum bid listing rules, and to maintain the Company's Nasdaq listing. Further, the Company will provide commentary on its regulatory strategy and ongoing drug development initiatives designed to advance its lead compound through Phase I and into Phase II trials.
It just seems like TMI: He said this, he did that. Sounds like one threw a temper tantrum and the other is punished. Maybe keep it discrete, or more discrete and professional. Sounds more like high school drama meets biotech.
I'm thinking that Mullan wanted to wait for the overseas trials to conclude before responding to the FDA, to bypass the bias of the supplement business missteps which have stigmatized the company here. Sounds like McDonnell was vehemently against that, and he and Chapman took matters into their own hands...and failed. Mullan is in damage control mode. Hopefully his vision is sharp, and as this comes to pass, ie., getting rid of the riff-raff, pieces start falling into place.
LOL. If only that were true. The reality is that Rock Creek would have been better off had he been doing nothing. At least, that is what Mullan wants us to believe. I'm all for transparency, but the tone of the 8k seems spiteful.
Lest there be any question about the scumminess of Slick J Willi, the Nicobine venture should rest those doubts. It is right up his alley though: a fad with an unknown safety profile; false claims regarding effectiveness of the product; good yet deceptive marketing; moving on/reinventing himself quickly after screwing over many people with reckless disregard; ambiguous ulterior motives.
Mullan should keep Rock Creek far, far away from anatabine ecigs, and far, far away from Scheming J Willi. J Willi is, without any question, more interested in becoming richer, than he is in helping people. He is the quintessential money hungry narcissist, and thus, cannot be trusted or believed.
To be successful, Mullan needs to make RCPI his baby: he needs to nurture and protect it...full time! Half-hearted leadership is partly responsible for the current predicament.
Chapman, and/or anyone in RCPI still affiliated in a personal way with JW, should be terminated. He is toxic.
Pheman-Could you furnish the portion of the 10k that shows JW's share count? I looked and looked, and couldn't find it.
How very disappointing to learn about all this corporate dysfunction. I guess the writing has been on the wall since JW's political scheming (and arguably, since his entreprenurial beginnings). It seemed possible that Mullan could have really turned this boat around. But then, you realize, he is spreading himself thin due to other leadership obligations. In hindsight, the screwing around of McDonnell and Chapman resulted from a disorganized hierarchy. I guess they should have cleaned up the scum that came with Jonnie from the outset (Chapman), or, at least, dedicated more time to running the operations and supervising the executives and board. In Chapman's defense, why, in February, is Rock Creek sending a (deficient) response to a hold, which was placed in August 2014!?
Be it sabotage, incompetence, or impatience by Chapman/McDonnell, Mullan, as CEO, has a duty to expedite the FDA response filing, and to 'manage' the executives and directors that he pays (in fact, WE pay!). As shareholders watching this gradually and painfully decline as long as is has, it is despicable. We are witnessing adults acting like children, playing a game that is way over their heads...with our investment at stake!
Amateurs and scumbags--boy did we pick a winner.
They have been marketed in the US since 2003 and 1996, respectively. Something is amiss with that blog post.
Curcumin proved effective at combating cancer
http://m.medicalxpress.com/news/2015-03-curcumin-effective-combating-cancer.html
What’s inflammation? How to decrease your disease risk
By Lacie GloverPublished February 25, 2015NerdWallet
http://www.foxnews.com/health/2015/02/25/whats-inflammation-how-to-decrease-your-disease-risk/
Foods That Fight Osteoarthritis & Inflammation
http://nutritionfacts.org/2015/02/03/foods-that-fight-osteoarthritis-inflammation/
Written by: Michael Greger M.D. on February 3rd, 2015
Foods That Fight Osteoarthritis & Inflammation
Osteoarthritis is the most frequent cause of physical disability among older adults in the world, affecting more than 20 million Americans. It is estimated that 20% of us will be affected in the coming decades and it is becoming more and more widespread among younger people. Can anti-inflammatory foods help with this disease?
Osteoarthritis is characterized by loss of cartilage in the joint. We used to think it was just mechanical wear and tear, but is “now generally accepted to be an active joint disease with a prominent inflammatory component.” This is supported by the fact that, for example, there is significantly higher production of inflammatory prostaglandins from tissue samples obtained from the knees of people suffering from the disease.
If the loss of cartilage is caused by inflammation, an anti-inflammatory diet may indeed help. A recent review concluded that using optimal nutrition and exercise as the “first-line” intervention in the management of chronic osteoarthritis could well constitute the best medical practice.
What does “optimal nutrition” look like? The China study “showed the serious health consequences of high consumption of pro-inflammatory foods (meat, dairy, fat, and junk) and low consumption of anti-inflammatory plant foods (whole grains, vegetables and fruits, and beans, split peas, chickpeas and lentils).” The unnatural Western diet “contributes to low-grade systemic inflammation, and oxidative tissue stress and irritation, placing the immune system in an overactive state, a common denominator of conditions such as arthritis.”
There are phytonutrients in plants that appear to help decrease the degradation of the joint cartilage, inflammatory activity, cell death and oxidative damage. This is based largely on in vitro studies, suggesting protective benefits of soy, pomegranates, citrus, grapes, green tea, and the curry powder spice turmeric. But my patients are people, not petri dishes. What role might the yellow pigment curcumin in turmeric play in the treatment of osteoarthritis?
Obesity doesn’t just put more stress on our joints. The fatty tissue inside our joints—like in the kneecap itself—is a source of pro inflammatory chemicals that have been shown to increase cartilage degradation. Curcumin may not only help prevent the release of inflammatory chemicals, but may also slow the formation of the fat pad in the first place. But this has all been in test tubes. There have been two clinical studies published to date.
The latest study took 50 patients suffering from mild-to-moderate knee osteoarthritis and gave them either the best available medical treatment, which included control with anti-inflammatory drugs and pain-killers, or the best available treatment along with some proprietary curcumin supplement. They looked at a number of different outcome measures, including the Karnofsky scale which goes up to 100 (normal, no evidence of disease), down to zero, at which you’re dead. The group with the added curcumin did significantly better, and were able to double their walking distance (see the results in my video, Turmeric Curcumin and Osteoarthritis). The curcumin group was also able to significantly decrease their drug use, side-effects, swelling hospitalizations, and other treatments.
But it doesn’t have to be some fancy proprietary formula. In the other study, “The efficacy of turmeric extracts in patients with knee osteoarthritis,” about a hundred sufferers were randomized to ibuprofen or concentrated turmeric extracts for six weeks, and the curcumin group did as good or better than the ibuprofen group. Even though ibuprofen is over-the-counter, it can cause ulceration bleeding and perforation of the stomach and intestines (that is, it can eat right through your stomach wall). In fact, that happened to someone in the study. Whereas the side-effects of curcumin include potentially protecting against a long list of diseases.
-Michael Greger, M.D
If Mullan & Co. have not spoken with the MJFF yet about funding, it may be in their (and our) best interest to do so:
Paprika protects against Parkinson's
http://www.ergo-log.com/paprika-protects-against-parkinson-s.html
It might be that people who eat lots of paprika or peppers are dramatically reducing their chance of developing Parkinson's disease. This is suggested by an epidemiological study that researchers at the University of Washington published in the Annals of Neurology. Paprika and peppers, but tomatoes too, contain nicotine, capsaicin and other substances that protect brain cells.
Parkinson's
In the first stages of Parkinson's, brain cells that produce dopamine die off. As a result, people with Parkinson's find movement increasingly difficult; their muscles start to stiffen and become painful, their enjoyment of life decreases and they lose their ability to make decisions.
Smoking and passive smoking protect against Parkinson's and this is probably because tobacco smoke contains nicotine [structural formula at right]. [Mov Disord. 2012 Jul;27(8):947-57.] That's not to say that smoking is 'therefore' healthy: the chance that if you smoke you won't get Parkinson's is pretty remote, but the chance that you'll die of lung cancer if you smoke is pretty high.
Plants in the nightshade family – potatoes, aubergines, tomatoes, paprika and peppers – also contain 2-7 mcg nicotine per kg. A normal diet easily provides more than 1 mcg nicotine per day, and several percent of the population consume more than 2 mcg nicotine per day. [J Agric Food Chem. 1999 Aug;47(8):3113-20.] To give you an idea: if you sit for three hours in a room filled with tobacco smoke, you'll consume 1 mcg nicotine. [N Engl J Med. 1993 Aug 5;329(6):437.]
Study
The researchers were curious whether people who consumed large amounts of nightshade family plants were less likely to develop Parkinson's, so they compared the eating patterns of 490 people who had just been diagnosed as having Parkinson's with those of a control group.
Results
The researchers discovered that green, yellow and red paprika and peppers protected against Parkinson's. Tomatoes protect too, but less so; potatoes and aubergines have no protective effect.
People who eat paprika or peppers daily halve their chance of developing Parkinson's compared with people who never eat these vegetables. The protective effect of paprika and peppers is greatest if you don't smoke.
Not only nicotine
The researchers believe that the protective effect of paprika and peppers is not just due to nicotine. Paprika also contains the nicotine analogue anatabine [structural formula at right]. Animal studies have shown that anatabine inhibits Alzheimer's, and who knows, maybe anatabine has the same effect on Parkinson's. [Eur J Pharmacol. 2011 Nov 30;670(2-3):384-91.]
Another group of substances found in paprika and pepper are the capsaicin analogues. The structural formula of capsaicin is shown here. These substances stimulate the TRPV1 receptor. According to some studies, high concentrations of capsaicin can damage brain cells via the receptor, but other animal studies suggest that capsaicin actually protects dopamine-producing brain cells. [Brain Res Bull. 2012 Nov 1;89(3-4):92-6.]
Ergonauts who are contemplating experimenting with these findings are perhaps best to confine themselves to vegetables rather than trying high-dose supplements.
Conclusion
"Epidemiological studies may shed further light on our somewhat novel hypothesis and findings", the researchers conclude. "Although they are consistent with the well-established inverse association between Parkinson's disease and tobacco use, it remains unknown whether nicotine reduces Parkinson's disease risk and whether TRPV1 agonists, including those in peppers, are neuroprotective or neurotoxic."
"Replication of our findings will be needed to strengthen causal inferences that might eventually lead to dietary or pharmaceutical interventions designed to help prevent Parkinson's disease."
Source:
Ann Neurol. 2013 Sep;74(3):472-7.
Human Immune System Itself Can Cure Alzheimer's Disease
By Saranya on February 08 2015 1:52 AM
http://au.ibtimes.com/human-immune-system-itself-can-cure-alzheimers-disease-1419027
Human immune system itself can cure Alzheimer's disease, reports researchers from the Keck School of Medicine of the University of Southern California (USC). Irreversible, progressive brain disease causing problems with memory, thinking and behaviour on aging is referred as Alzheimer’s disease.
Alzheimer’s disease is the most important public health issue of our period which has no real-time cure, said Terrence Town, PhD, professor of physiology and biophysics. He also added that the study demonstrates a way to wipe out the plaques built-up in the brain with the help of body’s immune response, bringing a new hope in cure for the ailment.
Alzheimer’s disease is the most common form of dementia often seen in elderly people, characterised by loss of memory and other mental functionalities. In Alzheimer’s disease, a sticky plaque built-up in the brain made of a special type of protein called beta-amyloid induces memory loss in the patients. The immune system that generally wipes out the toxic protein substances from the body is unable to clear the plaques as it becomes inefficient and imbalanced.
The researchers demonstrated that blocking a substance called the interleukin-10 in genetically modified mouse activates an immune response against the protein beta-amyloid, thereby clearing the plaques. As a result of the plaque clearance, brain cell damage and memory loss were restored in the mouse.
The mouse on immune response activation was reported to have behaved like other normal species without disease in memory and learning tests. The researchers added that further studies on the effectiveness of the drug in blocking interleukin-10 will be carried on the mice that are genetically engineered to develop Alzheimer’s disease.
There are about 36 million people in the world suffering from Alzheimer’s disease now, and if the same pace continues, the figure will reach 115 million by 2050, says the Alzheimer’s Society. Therefore, there is a big time need for an effective drug against Alzheimer’s disease.
To report problems or to leave feedback about this article, e-mail: saranya@ibtimes.com.au
This was already posted. I thought it was ridiculous that this was put on an MS board and picked up by other MS outlets. I still think it ridiculous, but realize now that it probably isn't a random association: the company likely had something to do with getting this info out to those sites. Perhaps we just learned of the first indication for Anatabine Citrate.
I find that 'plug' by MS-UK quite premature. eom
Check this company out: FLKS. They just had an IPO last week. Here is some mention of it on the Biotech Values board (#msg-110380384). Follow the thread and links to get an idea why some think this, and RCPI, is considered somewhat pseudoscience. Personally, I think it is ridiculous that RCPI (and FLKS) must go the FDA route (and get approval as a "prescription drug") to be able to sell their version of natural compounds. It is a glaring example of how the system meant to protect us may be doing the opposite, and costing us (and society) more in the process.
Btw, I wonder how much anatabine is in capsicum extract (bell pepper). It might be a good way for all those anatabiners to get their fix.
That's probably the earliest you would want a partnership, most of the time. However, if the money required to make it thru phII continues to significantly dilute our equity or increase our debt, then shit, sign away now. I think we've gotten to the point of no return when it comes to current shareholders equity: continued dilution or debt until a deal; no event in the near or foreseeable future to enhance real intrinsic value; considerable uncertainty and doubt as to the prospects of the compound and value of IP; and, mounting deferred liabilities wrt executive and BoD pay.
Too colorful to resist...
There are red flags. Then, there are much redder flags. Lol on the latter...
Research suggests anti-inflammatory protein may trigger plaque in Alzheimer's disease
{The good news is that I don't see any mention of anatabine's effect on IL-10}
http://www.eurekalert.org/pub_releases/2015-01/uof-rsa012215.php
UNIVERSITY OF FLORIDA
GAINESVILLE, Fla. -- Inflammation has long been studied in Alzheimer's, but in a counterintuitive finding reported in a new paper, University of Florida researchers have uncovered the mechanism by which anti-inflammatory processes may trigger the disease.
This anti-inflammatory process might actually trigger the build-up of sticky clumps of protein that form plaques in the brain. These plaques block brain cells' ability to communicate and are a well-known characteristic of the illness.
The finding suggests that Alzheimer's treatments might need to be tailored to patients depending on which forms of Apolipoprotein E, a major risk factor for Alzheimer's disease, these patients carry in their genes.
The researchers have shown that the anti-inflammatory protein interleukin 10, or IL-10, can actually increase the amount of apolipoprotein E, or APOE, protein -- and thereby plaque -- that accumulates in the brain of a mouse model of Alzheimer's, according to the study, published online today (Jan. 22) in the journal Neuron.
In the 1990s, researchers theorized that using nonsteroidal anti-inflammatory drugs, or NSAIDs, might protect people from the onset of Alzheimer's by dampening inflammation that released a cascade of harmful proteins. Though NSAIDs were shown to be effective in some studies, other research that evaluated a group of participants taking NSAIDs over time failed to show any clear protective benefit.
"There are many different kinds of NSAIDs," said Todd Golde, M.D., Ph.D., director of the Center for Translational Research in Neurodegenerative Disease and the paper's lead author. "Not all NSAIDs are equal, and it wasn't clear what else they were doing when they were addressing their intended target."
Previously, researchers hypothesized that a flood of proteins, called cytokines, involved in promoting inflammation in the brain contributed to the formation of plaque in Alzheimer's disease. However, in this publication, the UF researchers provide new evidence that anti-inflammatory stimuli may actually increase plaque.
"This is another piece of evidence that overturns the long-held hypothesis that a 'cytokine storm' creates a self-reinforcing, neurotoxic feedback loop that promotes amyloid-beta (plaque) deposition," said Paramita Chakrabarty, Ph.D., a member of the UF Center for Translational Research in Neurodegenerative Disease, an assistant professor in the UF College of Medicine department of neuroscience and the paper's co-author.
The researchers said that a person's risk of developing Alzheimer's hinges on the relationship between IL-10 and APOE. APOE clears the cell of many different proteins, including the protein amyloid-beta, which contributes to the buildup of plaque. But there are several different forms of APOE in cells, which differ from each other by only one or two amino acids. The form called APOE4 is the largest known genetic risk factor in Alzheimer's disease, while APOE2 is thought to be protective, Golde said.
"About 15 to 17 percent of the population has the APOE 4 allele, and about 50 percent of people with Alzheimer's have it," Golde said.
In this case, the authors showed that the anti-inflammatory protein IL-10 actually increases levels of all types of mouse APOE, which resembles human APOE. In the mouse model, APOE binds with amyloid-beta rather than clearing it from the brain, accelerating buildup of plaque in the brain of a mouse with Alzheimer's. How an anti-inflammatory therapy based on IL-10 expression might alter risk for Alzheimer's may depend on the genetic variant of APOE protein the person is carrying. If the person has an APOE4 allele the researchers predict the risk for Alzheimer's would increase.
"In one way, this study offers additional insight into how environmental influences interacts with people's underlying genotypes to alter their risk for diseases," Golde said. "We know that people are exposed to various inflammatory or anti-inflammatory stimuli throughout their lives. Depending on what their genotype is, that exposure may in some cases protect them from Alzheimer's, or, in other cases, increase their risk for Alzheimer's."
The research was funded in part through an $8.4 million grant to speed up the process of finding therapies for Alzheimer's disease from the National Institutes of Health's Office of the Director, with additional funding from the National Institute on Aging and the Ellison Medical Foundation. Next, the researchers plan to carry out more thorough and mechanistic studies to exactly understand how an increase in APOE protein induced by IL-10 will affect amyloid plaque deposition in mice carrying different alleles of human APOE.
I think he is trying to say that this is strictly business; not a love affair. Quotient was hired by a company willing to pay them for their service. Getting giddy over this is just something you are projecting on everyone else. There is no correlation between the efficacy of anatabine and the hiring of Quotient. None.
The industry theme song?
Gfp old chap, how do you be? How is our resident science nerd, conspiracy theorist, and gun enthusiast doing (and fellow music appreciator)? Glad to see you keeping up with things.
My latest venture is etrm. They just got fda approval for a novel medical device to treat obesity. The device (the "Maestro", in part) is placed in the abdomen and has electrodes which send nerve impulses to your brain to tell you that you're full. With pills and riskier invasive surgeries the primary medical options, this could really find a niche. I bought at 1.38, after it spiked to 2.04 on the approval, and now it is practically trading at the pre-approval price. The stock has mostly been a dog for years. The market is underwhelmed, but I think they could be a sleeper.
My handle is haysaw, and I too, am a cortex loser :)
We are the Confederacy of Dunces, welcome...
Re: LLTP. Thanks - It appears to be below my threshold for risk (which is already pretty low, unfortunately), but has potential. Having a unique profile (naltrexone spray) seems like a good product for overdoses outside a medical facility. I see there is a 1:100 split coming up at some point (unless it already happened - yikes if it did), so it might be worth watching.
They are going after the same target (opiate overdose/respiratory depression) as another dog of mine, Cortex (CORX), which also showed incredible potential...once. It does look as though Lightlake's product would be much closer to approval/market than Cortex, given naltrexone is already an approved drug. However, Cortex would seem to have stronger IP and more ultimate upside. Since both those companies trade @ same price with @ the same MC, maybe there could be a synergistic merger in the future...misery loves company, lol.
Sure. Just realized about 10min ago I did not include one:
http://www.sciencedaily.com/releases/2015/01/150112110405.htm
Interesting research, and a similar concept to Rock Creek's. The aerosol version/method looks like an angle RCPI should explore (or even, as others have pointed out, a vaporizer compound):
Curcumin's ability to fight Alzheimer's studied
Date: January 12, 2015
Vanderbilt University Medical Center
One of the most promising new treatments for Alzheimer’s disease may already be in your kitchen. Curcumin, a natural product found in the spice turmeric, has been used by many Asian cultures for centuries, and a new study indicates a close chemical analog of curcumin has properties that may make it useful as a treatment for the brain disease.
“Curcumin has demonstrated ability to enter the brain, bind and destroy the beta-amyloid plaques present in Alzheimer’s with reduced toxicity,” said Wellington Pham, Ph.D., assistant professor of Radiology and Radiological Sciences and Biomedical Engineering at Vanderbilt and senior author of the study, published recently in the Journal of Alzheimer’s Disease.
Accumulation and aggregation of protein fragments, known as beta-amyloid, drives the irreversible loss of neurons in Alzheimer’s disease.
Developing small molecules to reduce this accumulation or promote its demolition is crucial, but the ability of these small molecules to cross the blood-brain barrier has been a restricting factor for drug delivery into the brain.
Pham and colleagues at Shiga University of Medical Science in Otsu, Japan, developed a new strategy to deliver a molecule similar to curcumin more effectively to the brain.
“One of the difficulties in the treatment of Alzheimer’s disease is how to deliver drugs across the blood brain barrier,” he said. “Our body has designed this barrier to protect the brain from any toxic molecules that can cross into the brain and harm neurons.
“But it is also a natural barrier for molecules designed for disease-modifying therapy,” Pham said.
To work around the problems of giving the drug intravenously, the researchers decided to develop an atomizer to generate a curcumin aerosol.The Japanese researchers developed a molecule similar to curcumin, FMeC1, which was the one actually used in this study.
“The advantage of the FMeC1 is that it is a perfluoro compound, which can be tracked by the biodistribution in the brain noninvasively using magnetic resonance imaging. Curcumin is a very simple chemical structure, so it is not expensive to generate the analog,” Pham said.
“In this way the drug can be breathed in and delivered to the brain,” he said, noting that nebulizers are out in the market already, and are relatively inexpensive.
“In this paper we also showed that delivery to the cortex and hippocampal areas is more efficient using aerosolized curcumin than intravenous injection in a transgenic mouse model of Alzheimer’s disease,” Pham said.
I believe the 180 day extension was already given. That would mean they have to implement the reverse split by the April 27th deadline.
The Brain Preservation Diet: Eating to Save Brain Cells
http://news.yahoo.com/brain-preservation-diet-eating-save-brain-cells-153938520.html
When New York-based filmmaker and musician Max Lugavere was his mother Kathy's patient wingman a few years ago, he became frustrated by what he calls a "diagnose and adios" approach to treating her memory loss. "Basically they tell you what they think is going on, they prescribe drugs which aren't very effective and that's it," Lugavere says. "I saw very little in the way of lifestyle or diet interventions."Lugavere took his mother to neurology departments at university hospitals throughout the country to figure out what was wrong, but her condition was hard to pin down. "I sort of had to put on my detective hat to use my understanding of science and biology," Lugavere says.Lugavere's mother still hasn't been diagnosed with one precise condition, but her "confluence of mysterious symptoms" point to cognitive impairment, memory loss andParkinsonism. She's being treated for memory loss and is stable. Meanwhile, Lugavere has started taking proactive steps toward preventing his own potential disease onset. While researching his mother's condition, he discovered something he says was once taboo to imply: You can helpprevent Alzheimer's disease. At least in part. According to an analysis in the Lancet Journal of Neurology last August, more than half of Alzheimer's cases worldwide might be attributed to potentially modifiable risk factors. And one of these risk factors is diet."I came across some very interesting insights," Lugavere says. "They found striking similarities between the brain cells in Alzheimer's disease and the muscle cells in people with Type 2 diabetes."Studies have shown a correlation between high blood sugar and increased risk of dementia, adds David Perlmutter, a neurologist based in Naples, Florida, who is internationally recognized in the field of nutritional influences in neurological disorders. For example, one study published in the New England Journal of Medicine measured blood sugar in 2,000 people for seven years and found that those with higher blood sugar levels were at a significantly higher risk of dementia, Perlmutter continues. "There's a perfect correlation between sugar and Alzheimer's disease." The exact reason why that's the case isn't yet known, but some researchers believe the insulin resistance in people with high blood sugar affects brain cells.Higher blood sugar levels also correlate with brain shrinkage, Perlmutter adds. And the brain consumes a lot of the calories that we take in -- another reason to be mindful of the content of those calories, Lugavere says. "The brain at rest uses as much energy as one leg during a marathon," he says. "It's a very hungry organ."
Low-Carb, High-Fat Diet
If there's one consistent message across most diets these days, it's to consume carbohydrates sparingly. The same is true for brain health. "There isn't a special brain-smart diet that is different than a heart-healthy diet or a diabetes prevention diet," Perlmutter says. "There is really one dietary approach." That approach involves reducing free radicals and inflammation through the body, he continues. Specifically in the brain, inflammation destroys brain cells and interferes with cognitive function."Inflammation is the cornerstone of everything that can go wrong in the brain," Perlmutter says, adding that 99 percent of the genetic material in the body is contained in the gut bacteria, or micro-biome. Research shows that this good bacteria in the lining of our gut contributes to the regulation of signaling between the gastrointestinal tract and other organs and the central nervous system.Refined carbohydrates like white bread incite inflammation by firing up proteins called cytokines, while whole carbohydrates such as fruits, vegetables and legumes fight inflammation. "Anything we can do to make sure our bodies are using glucose as efficiently as possible makes sense for our brain health," Lugavere says. Because the brain is such a fatty organ, eating good fats is also important. These include coconut oil, salmon and grass-fed red meat, he adds.Richard Isaacson, director of the Alzheimer's Prevention Clinic at the Weill Cornell Memory Disorders Program, designs personalized nutrition plans for people at risk of Alzheimer's disease because of a family history of the disease. "One of the most important things is that anyone can take control of brain health by changing the food they eat," Isaacson says. "There isn't a one size fits all."That said, there's strong evidence that the Mediterranean diet is good for brain health, as well as elements of the paleo diet, he adds. He recommends consuming a lot of omega-3s in fatty fish, flavonoid-rich berries and lean meats such as chicken and turkey.
Don't Delay Eating for Brain Health
Lugavere, who's 32, adopted his own brain-healthy diet shortly after delving into research for his mother, and after a blood test revealed that he has both the genetic variants and high levels of an amino acid that put him at increased risk of dementia. "Based on everything I know, I have opted to eat a diet low in carbs and high in good fats," he says. "I feel as lean and strong as I've ever been."Lugavere just finished making a documentary film called "Bread Head," that includes interviews with several top Alzheimer's researchers in the U.S. who endorse a low-carb diet for brain health. One researcher, Suzanne de la Monte, an associate professor of pathology and medicine at Brown University, coined the concept that Alzheimer's is Type 3 diabetes because of the strong correlation between carb-rich foods and memory loss.Lugavere wants to use his film to reach as many people as possible, including peers. That could be a significant audience, since 5.2 million people in the U.S. had Alzheimer's disease in 2014, and that number is expected to triple by 2050. The key, Lugavere says, is to reach enough people in time, since changes in the brain occur decades before symptoms of disease appear. "Prevention really is the new frontier," he says. "I hope I can help it get here faster. We don't have time to lose.
"Kristine Crane is a Patient Advice reporter at U.S. News. You can follow her on Twitter, connect with her on LinkedIn or email her at kcrane@usnews.com.
No, but $5 p/s (or $1B MC) for that progression is. Try and keep up Jay, perhaps by just listening and learning.
Btw-You do not want a partnership this early. It would not be beneficial to shareholders in the long run, unless they are perpetually strapped for cash and continue to raise cash via the dilution or debt route. If that's the case, then they should take what they can get when they can get it, but the terms wouldn't be very good.
Think about it. If everything does work out and RCPI is involved in a PhII study by the end of the year, does that justify a $1B market cap? I say no. Not by a long shot. One in a million perhaps. But maybe,if they do the r/s, chances are much, much better.
Don't let me discourage you from fantasizing though...
It's a pragmatic approach. All my initiated arguments can be rooted in that.
No need to be sorry...we live, we learn, we share. What I didn't gain (from Corx) in equity, I gained in wisdom. I am long RCPI, and I will continue to respond to nonsense. If I'm busting balls, then balls need to be busted. I am most certainly not rubbing anyone's losses in. To the contrary, I'm trying to rub the nonsense out of all you 'lost' ones.
This is tedious...but I'm game. I know what I know. I don't claim to know what I don't know. You, however, do just that. If you are right in all these future 'happenings', I will give you credit -- not for your intelligence or common sense, but for your persevering faith and surprising sixth sense. I'm curious to know if there is a light at the end of the tunnel for you. I'm curious to know if there was a light at all...or even a tunnel to reach it. Hmmmm...
I love how you tell me you're getting under my skin (once again, claiming to know what you don't know). The paradox is not lost on me: It is obvious that I've gotten under yours. You must have the skin of an onion...lol. God bless ya' too!
Ps. I don't think Corx ever went below a penny or two. And while I did not go broke, I did take a bath. But I also traded some at lower prices to recover something. Smart, right? Sounds familiar? Hope the story ends differently here though (even though, technically, that story isn't over yet. As a matter of fact, they will be at the same conference in a couple days. Coincidence, huh?).
Never mind, dude -- you are incorrigible. Just ignore me, Please.
I will...later. Be careful getting 'lost' in the science though. I assure you: there is a shitload more people that go broke betting on a biotech that they think is a game changer, then there are game changers. That is the truth. Don't think you know more than all those other people who thought the same thing in their biotech.
Go ahead, dude, quiz me. Never mind, don't. Like I said: it is not about me and you, or the others like you. Let's have a board discussion on what you think is relevant, and I will respond or discuss what I think is relevant. Fair enough? Everyone is welcome to contribute. Ball's in your court...shoot.
dude - get out of your own way. Just respond without the attitude. Did I say they had to complete the split by that time? I highlighted that part for Christ's sake. The point is, they have to get the ball rolling well before the extension period is over. That means they can't just wait until April 27th and 'hope' the stock price is over $1. Nor does it mean they will ignore the r/s vote (which will be approved) if the stock surpasses, and holds, $1 p/s. The discussion could be pleasant if you refrain from a defensive posture. Give it a try. Let's work together.